A tale of two sites: how inflammation can reshape the microbiomes of the gut and lungs by Scales, Brittan S. et al.
Review
A tale of two sites: how inflammation can
reshape the microbiomes of the gut
and lungs
Brittan S. Scales, Robert P. Dickson, and Gary B. Huffnagle1
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School,
Ann Arbor, Michigan, USA
RECEIVED MARCH 2, 2016; REVISED MAY 24, 2016; ACCEPTED JUNE 6, 2016. DOI: 10.1189/jlb.3MR0316-106R
ABSTRACT
Inflammation can directly and indirectly modulate the
bacterial composition of the microbiome. Although
studies of inflammation primarily focus on its function to
negatively select against potential pathogens, some
bacterial species have the ability to exploit inflammatory
byproducts for their benefit. Inflammatory cells release
reactive nitrogen species as antimicrobial effectors
against infection, but some facultative anaerobes can
also utilize the increase in extracellular nitrate in their
environment for anaerobic respiration and growth. This
phenomenon has been studied in the gastrointestinal
tract, where blooms of facultative anaerobic Gammap-
roteobacteria, primarily Escherichia coli, often occur
during colonic inflammation. In cystic fibrosis, Pseudo-
monas aeruginosa, another Gammaproteobacteria fac-
ultative anaerobe, can reduce nitrogen for anaerobic
respiration and it blooms in the airways of the chronically
inflamed cystic fibrosis lung. This review focuses on the
evidence that inflammation can provide terminal electron
acceptors for anaerobic respiration and can support
blooms of facultative anaerobes, such as E. coli and
P. aeruginosa in distinct, but similar, environments of the
inflamed gastrointestinal and respiratory tracts.
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Introduction
The host immune system is often considered metaphorically to
be “at war” with microorganisms, in which the immune system
mounts a host defense against an invading army of potential
pathogens. In this context, inflammation is thought of as a
weapon that produces activated cells and antimicrobial mole-
cules to destroy the invaders. This metaphor would work if the
body during health were sterile; however, it is not. In actuality,
complex communities of microorganisms live on every surface
area of the human body during health and those communities
change, but still persist, during inflammatory responses. Even
areas of the body once considered sterile, such as the lungs, are
now known to harbor low levels of bacteria during health [1, 2].
Certain bacteria, primarily those found in the Proteobacteria
phylum, contain the metabolic capacity to utilize inflammatory
byproducts for their survival [3]. During chronic inflammation
these Proteobacteria “bloom” (i.e., increase in relative abun-
dance) within a microbiome and outcompete bacteria that lack
the metabolic capacity to benefit from inflammation. Although
this connection between inflammation and Proteobacteria
bloom has been recognized in the gastrointestinal microbiota
literature, we are only beginning to appreciate that the same
mechanisms may apply to the respiratory microbiota and the
bloom of Pseudomonas aeruginosa during CF and potentially other





Large-scale disturbances of the bacterial community composition
in the GI tract can affect the health of the host, a phenomenon
known as “dysbiosis” [4–6]. In a state of health, the GI tract
contains a large, complex microbiota that is dominated by
obligate anaerobes from the phyla Bacteroidetes and Firmicutes,
with members of the phyla Proteobacteria and Actinobacteria
occurring in lower numbers. Antibiotics, diet and injury/changes
in the epithelium can result in dysbiosis. One increasingly
recognized factor contributing to dysbiosis in the gut is the onset
of inflammation. During GI inflammation, the obligate anaer-
obes of the Bacteroidetes and Firmicutes phyla decrease in
relative abundance, whereas Proteobacteria increase to become
the most prominent phyla in the gut, largely attributable to
outgrowth of Gammaproteobacteria, which include the
Enterobacteriaceae.
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A bloom of Enterobacteriaceae in response to GI inflam-
mation has been demonstrated in numerous contexts. In both
infection-induced and genetic mouse models of IBD, micro-
biota dysbiosis in response to inflammation is marked by a
large relative increase in Enterobacteriaceae [3, 7–18]. This
finding has been demonstrated for Escherichia coli, Salmonella
typhimurium, and Klebsiella pneumoniae. Individuals with IBD are
known to have an altered gut microbiota marked by an
increased relative abundance of Enterobacteriaceae, as well as
other members of the Gammaproteobacteria class and
Proteobacteria phylum [19–24]. These clinical and experi-
mental observations support the concept that some aspect of
Gammaproteobacteria physiology provides them with a growth
advantage over other members of the indigenous microbiota
on the inflamed GI mucosa.
BACTERIAL ANAEROBIC RESPIRATION IN
THE GI MUCOSA
The healthy colon is an anaerobic environment and the energy
needs of the bacteria in the GI microbiome are met primarily
through fermentation. The availability of specific terminal
electron acceptors in the environment is a major factor
influencing the composition of the bacterial microbiome. In the
absence of inflammation, the GI mucosa lacks sufficient
quantities of molecular oxygen or NO3
2 for Enterobacteriaceae
to carry out oxidative phosphorylation via the electron transport
chain, thereby limiting the growth of these organisms.
In sharp contrast, it has recently been recognized that
inflammation changes the metabolic environment of the mucosa
by providing the terminal electron acceptors needed for
anaerobic respiration by Enterobacteriaceae, thereby allowing
them to outgrow (or “bloom”) the other resident anaerobes that
primarily use fermentation for their energy needs (recall that
fermentation generates less ATP than respiration) [3, 25]. One
of the central antimicrobial actions of inflammatory host cells is
the production of ROS, primarily in the form of O2
2, and RNS,
primarily in the form of NO [26]. O2
2 and NO can react
together to produce ONOO2, which decomposes into NO3
2 and
(NO2
2) (for a detailed description of the reaction, please see ref.
27). Extracellular NO3
2 can be used as a terminal electron
acceptor to support anaerobic respiration and growth of
Gammaproteobacteria in vivo via denitrification [3, 7–13].
RNS produced via iNOS in myeloid cells during inflammatory
reactions have long been held to play a major role in the
antimicrobial activity of these cells [28–37]. Antimicrobial activity
can be mediated by iNOS and RNS directly, as well as induction
anti-microbial peptide expression and innate immune system
signaling. However, iNOS/RNS can also promote the coloniza-
tion of inflamed mucosal surfaces by providing a selective
advantage for denitrifying facultative anaerobic bacteria, such as
E. coli, S. typhimurium, K. pneumoniae and most Gammaproteo-
bacteria, including Pseudomonas aeruginosa [3]. NO3
2 reductase
activity is critical for the utilization of NO3
2 as a terminal
electron acceptor. Winters et al. [3] performed comparative
genomics to determine the predicted presence of NO3
2
reductase activity across different bacterial phyla. As shown in
Fig. 1 (reprinted from their study [3]), members of the
Gammaproteobacteria had the highest prevalence of NO3
2
reductase activity, with the highest percentage found in the
Enterobacteriaceae. In contrast, members of the Bacteroidia and
Clostridia classes, which are obligate anaerobes and the major
members of the gut microbiome in the absence of inflammation,
have low to no NO3
2 reductase activity. This genomic data has
been used to support the model that the availability of host-
provided NO3
2 promotes the bloom of Gammaproteobacteria




E. coli has been shown to utilize NO3
2 provided through host
inflammation for growth through nitrogen respiration [13, 38].
E. coli is able to reduce NO3
2 to ammonium through a 2-step
dissimilatory NO3
2 reduction pathway (KEGG: http://www.
genome.jp/kegg-bin/show_pathway?org_name=eco&map-
no=00910&mapscale=&show_description=hide). As displayed in
Fig. 2, NO3
2 is first reduced to NO2
2 by NO3
2 reductase,
followed by reduction of NO2
2 to ammonium by NO2
2
reductase. Nonpathogenic E. coli strain MG1655 displays in-
creased in vitro growth under low-oxygen conditions if exoge-
nous NO3
2 is provided [38]. In the same study, NO2
2 and
ammonium was shown to increase proportionally with NO3
2
supplementation but decreased disproportionally with O2 con-
centration. The NO3
2 reductase enzymes all require a molyb-
denum cofactor in the active site to function, and this has been
used to demonstrate the requirement for NO3
2 reductase. An
E. coli mutant strain that lacked the molybdenum binding site in
the NO3
2 reductase enzyme (moaA) was outcompeted by the
wild-type E.coli strain in NO3
2-supplemented cultures [13]. In 2
different mouse models of intestinal inflammation, NO3
2 levels
were increased in the cecal mucus layer during inflammation,
and wild-type E. coli also outcompeted moaA mutant strains.
Similar results were seen for NO3
2 reductase deletion mutants.
Most strikingly, since iNOS is the sole source of NO3
2 during
inflammation, an iNOS inhibitor abolished the competitive
advantage of wild-type E. coli over the moaA mutant. Thus, these
experiments have directly demonstrated the link between host
inflammation, iNOS, RNS, and bacterial anaerobic respiration as
a mechanism that can provide a growth advantage for Enter-
obacteriaceae in the GI tract during disease.
CF AND CHRONIC PULMONARY
INFECTION BY P. AERUGINOSA
CF is a genetic disease where mutations of the CFTR gene lead to
increased mucus production and chronic bacterial colonization
in the lower airways [39, 40]. The respiratory epithelial cells are
unable to properly secrete chloride into the airway surface liquid,
resulting in dehydrated airway secretions that cause increased
mucus viscosity and decreased mucociliary clearance [41, 42].
Because of the increased availability of nutrient-rich mucus and
dysregulation of mucociliary clearance, bacterial counts mark-
edly increase ($10,000-fold), and a complex microbiota develops
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in the CF lung [40]. As the disease progresses and worsens, the
microbial community decreases in diversity until 1 dominant
microbe prevails; in most cases, this dominant organism is
P. aeruginosa [43]. Once a chronic P. aeruginosa infection is
established, it cannot be cleared by antibiotic treatment and
typically persists until the end of the patient’s life [44].
ANAEROBIC RESPIRATION IN
P. AERUGINOSA
P. aeruginosa has long been held to be an obligate aerobic
bacterium; however, recent studies have highlighted that this is
not true. P. aeruginosa has a highly branched respiratory system
for growth under both microaerophilic and anaerobic
conditions. Experimental evidence suggests that P. aeruginosa
prefers growth under microaerophilic conditions. In simulated
growth experiments, P. aeruginosa showed its highest growth
rate at 1% partial pressure of oxygen when compared to 5, 10,
and 50% partial pressure of oxygen [45]. P. aeruginosa has 2
terminal oxidases that assist in growth and help create
physiologic microaerobic conditions: the high-affinity oxidase
cytochromes Cbb3-1 and -3-2. The cbb3 oxidase genes are
constitutively expressed, even in aerobic conditions, which is an
unusual feature of P. aeruginosa biology, as these oxidases are
typically repressed in the presence of high environmental
oxygen [46]. In addition, P. aeruginosa isolated from CF airways
are known to overproduce the exopolysaccharide alginate,
which physically restricts the diffusion of oxygen into the cell
Figure 1. NO3
2 reductase capability within major
phyla. NO3
2 reductase activity (E.C.1.7.99.4) was
screened in 2476 genomes deposited within the
KEGG (release 67.1). Prevalence of NO3
2 re-
ductase ability was calculated as the fraction of
genomes containing NO3
2 reductase genes per
total genomes within each phyla (outer ring).
Ubiquitous phyla are those commonly present in
the gut microbiota, whereas rare phyla are those
less commonly found in the gut microbiota (inner
ring). Sector size is not proportional to the
relative abundance of the phyla. Figure first
published and reprinted here with permission
from Winter et al. [3].
Figure 2. Nitrogen respiration pathways in E. coli
and P. aeruginosa. The nitrogen reduction enzy-
matic pathways in commensal E. coli strain
MG1655 and in P. aeruginosa strain PAO1. Each
rectangle represents an enzyme, and the letters
inside each rectangle represent the protein com-
ponents of that enzyme. The rectangles are
colored according to the presence of that enzyme
in E. coli (light green) or P. aeruginosa (light
turquoise). Solid arrows: possible directions in
which the enzymatic reaction can occur; dotted
arrows: actual direction of the indicated pathway.
Diagram based on the information provided
by KEGG.
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and blocks the cell from oxidative stress [45, 46]. Low oxygen
additionally triggers the production and release of important
virulence factors, including elastase and pyocyanin [45].
Maintaining physiologic low-oxygen environment is likely an
important aspect in P. aeruginosa colonization and pathogenesis.
When oxygen levels drop sufficiently, such that no molecular
oxygen is available for aerobic respiration, P. aeruginosa is able to
respire and grow through the denitrification pathway. Figure 2
displays the nitrogen reduction ability of P. aeruginosa alongside
of E. coli and Fig. 3 displays a more in-depth model of how we
believe denitrification occurs at the cellular level in P. aeruginosa.
In denitrification, nitrogen oxides are utilized as alternative
terminal electron acceptors. Complete denitrification consists of
4 steps: (1) NO3
2 is reduced to NO2
2; (2) NO2
2 is reduced to
NO; (3) NO is reduced to N2O and 4) N2O is reduced to N2. A
reductase enzyme catalyzes each one of these steps. The genes
required to produce the denitrification enzymes and proteins
that regulate the anaerobic respiration system are arranged in 3
genomic clusters. NO3
2 reduction genes are found in the narXL-
narK1K2GHJI (PA3871-PA3880) cluster; NO2
2 and NO reduction
genes are arranged in the nirSMCFDLGHJEN-norBCD (PA0509-
PA527.1) cluster and the N2O to N2 reduction genes are found in
the nosDFLRYZ (PA3390-PA3396) cluster [46, 47]. Multiple steps
in this pathway contribute to the generation of a proton motive
force, primarily reduction of NO3
2 to NO2
2 by Nar and
reduction of NO by cNOR [46] (Fig. 3). However, in order for
nitrogen reduction to confer a growth advantage for P. aeruginosa
there needs to be an abundance of available nitrogen in the
CF lung.
CF, INFLAMMATION, AND P. AERUGINOSA
The substrates for denitrification can become available for
anaerobic respiration through the production of RNS by
inflammatory cells in mucus-rich regions of CF lungs [46, 48, 49].
The mucus within the CF lung is thick and mostly stagnant [48].
Upon infection, P. aeruginosa forms biofilms within the thick
mucus, and these biofilms become surrounded by high densities
of neutrophils that deplete the surrounding mucus of molecular
oxygen through the production of ROS and RNS [50–52]. Direct
in situ measurements of oxygen in CF sputum have confirmed
that it ranges from microaerobic to anaerobic [53]. The presence
of obligate anaerobes in the CF sputum and upregulated
expression of the global anaerobic regulator Anr in P. aeruginosa
isolates from CF-infected patients further demonstrate the lack of
molecular oxygen availability in the CF lung [54, 55]. Analysis of
the regulatory networks within P. aeruginosa reveals a complex
system that actually limits the exposure of the bacterial cell to
molecular oxygen (O2), even under fully aerobic conditions. As
discussed earlier, P. aeruginosa encodes a fully functional electron
transport system that utilizes NO3
2 or NO2
2 as a terminal
electron receptor for anaerobic respiration, via reduction of N3
to N2 (“denitrification”). The first step in this process is mediated
by NO3
2 reductase, encoded by narG. Mutants mutated in the
2-component NO3
2 sensor-response regulator, and in membrane
NarG display altered motility and biofilm formation compared to
wild-type P. aeruginosa PAO1 [49].
We propose the model in Fig. 4; that analogous to the
situation in the GI tract, inflammation in the CF lung likely
provides the NO3
2 substrates for P. aeruginosa to grow via
nitrogen respiration. The CF lung is chronically inflamed,
irrespective of infection and lung disease. Multiple studies
have found evidence of chronic inflammation in the CF lung,
even in the absence of bacterial infection or the onset of lung
disease [56–58]. Partly because of the chronic state of
inflammation, the sputum within the CF lung contains
sufficient nitrogen products to support growth of P. aeruginosa
via anaerobic denitrification. Both neutrophils and alveolar
macrophages found in CF sputum produce RNS and ROS [51,
59, 60]. Activated macrophages can release NO continuously
for weeks, such that, during chronic inflammation, NO
concentrations in the local environment can reach highly
cytotoxic levels [59]. The continual release of NO from
immune cells leads to increased levels of NO3
2 and NO2
2 in
the CF sputum [61]. As stated previously, NO and O2
2 react to
form ONOO2, which is then catalyzed into NO3
2 and NO2
[27]. For every mole of ONOO2 created, ;0.7 mole of NO3
2
and 0.3 mole of NO2
2 is produced [27]. NO3
2 is also
produced when NO is oxidized by the flavohemoglobin [62].
This process is necessary to protect P. aeruginosa from killing by
NO from inflammatory cells [27]. In support of the frequency
of the above reactions, exhaled NO from patients with CF is
Figure 3. Proposed denitrification model in
P. aeruginosa. Model built based on information
provide in Williams et al [80]. Nar, respiratory
NO3
2 reductase; Nap, periplasmic NO3
2 reduc-
tases; Nir, NO2
2 reductase; Nos,nitrous oxide
reductase; Nor, nitric oxide reductase; NarK1/2,
putative NO3
2– NO2
2 antiporter; Cytc, cyto-
chrome; Q, quinone; Nuo, NADH quinone
oxidoreductase 1. Sizes of proteins are not
to scale.
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lower than that from non-CF individuals, whereas NO3
2 levels
are considerably higher [61, 63–65]. The above reactions
produce enough substrate for P. aeruginosa to utilize de-
nitrification for growth [27]. P. aeruginosa increases in relative
abundance, leading to a decrease in overall diversity and
dysbiosis in the microbial community. Thus, one of the
consequences of the upregulated host inflammatory response
in patients with CF is the production of terminal electron
acceptors for anaerobic respiration that allow P. aeruginosa to
grow, persist, and outcompete all other microbial members of
the CF lung microbial community.
Inflammation is a common feature of chronic respiratory
diseases such as asthma and chronic obstructive pulmonary
disease [2, 66, 67]. It has been observed in several studies that
the relative proportion of Proteobacteria in the lungs increases
during disease. Less is known about the relationship between
inflammation and bacterial outgrowth in these diseases,
compared to the state of the field in CF. However, it seems
likely that comparable mechanisms are at play in these
obstructive airway diseases.
COULD THERE BE INFLAMMATION/
BACTERIAL COLONIZATION
FEEDBACK LOOPS?
Evidence suggests that Gammaproteobacteria not only benefit
from the effects of inflammation, they also contain molecular
components that directly enhance the inflammatory response.
MAMPs on the surface of bacteria interact with receptors on
Figure 4. How inflammation affects the microbiota at a body site. Inflammatory cells release O2
2 and NO into the local environment. These are
transformed into NO3
2, which is then utilized by facultative anaerobes as a nutrient source. Facultative anaerobes, primarily Gammaproteobacteria,
increase in relative abundance, leading to a decrease in overall diversity and dysbiosis in the microbial community. Dysbiosis in the microbiota can
fuel the inflammatory state, leading to a feedback-loop–like state at the body site.
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immune cells to initiate inflammation. One of the most potent
MAMPs expressed by Gram-negative bacteria is LPS, which
interacts with TLR4 on immune cells [68]. The lipid-A moiety of
LPS is required for its endotoxic ability and is composed of a 1,49-
bis-phosphorylated diglucosamine backbone attached with 5 or 6
acyl chains. Two genes determine how LPS is acylated; bacteria
with LpxL have LPS with 5 acyl (penta-acylated) chains and
bacteria with both LpxL and LpxM have 6 acyl (hexa-acylated)
chains. LPS that are penta-acylated are 100-fold less immunos-
timulatory when bound to TLR4 than LPS that is hexa-aceylated
[69]. Although the LpxL gene is found in most Gram-negative
bacteria, Gammaproteobacteria carry both the LpxL and LpxM
genes and, therefore, have the more immunostimulatory version
of LPS. The lungs of individuals with difficult asthma have up to a
7-fold increase of hexa-acylated LPS-producing bacteria than the
lungs of healthy individuals, suggesting there is a link to
inflammatory respiratory disease and the presence of more
immunostimulatory LPS-producing bacteria [69]. In fact, the
difference in immune induction between commensal Prevotella
sp. and COPD/asthma-associated Proteobacteria is likely related
to differences in LPS structure [68, 70]. In addition to LPS
induction of TLR4, bacteria can also induce an immune response
through a TLR9 interaction with unmethylated CpG motifs [71].
The optimal motif for inducing an immune response in humans
is GTCGTT [72], and the optimal motif for activating mouse and
rabbit immune cells is PuPuCGPyPy (Pu is purine and Py is
pyrimidine) [73]. Certain members of the Gammaproteobac-
teria, including P. aeruginosa, have high frequency of both
GTCGTT and PuPuCGPyPy motifs [74]. The high level of these
immunostimulatory motifs would lead to a higher induction of
inflammation when the bacteria are phagocytosed by immune
cells. A feedback loop is thus envisioned where the same bacteria
that contain the most immunostimulatory molecular compo-
nents are the same bacteria that benefit most from an
inflammatory environment.
Another potential feedback loop that occurs between
bacterial colonization and respiratory inflammation occurs
during exacerbations of respiratory diseases. Exacerbations are
marked by rapid increases in inflammation, which lead to a
worsening of disease symptoms and a reduction of respiratory
function [75]. The increase in inflammation during exacer-
bations leads to an increase in inflammatory byproducts, such
as iNOS released by neutrophils, and an increase in mucus
production, which reduces the oxygen tension of the re-
spiratory environment [53]. These changes in the lung
environment alter the bacterial community by selecting for
specific microbes. Paired specimen studies examining bacte-
rial communities before and after exacerbations during
chronic lung disease have found a community shift away from
Bacteroidetes, toward an increase in Proteobacteria [76–78].
Proteobacteria contain multiple immunostimulatory molecu-
lar components (such as lipid-A moieties and CpG motifs) that
further increase inflammation, leading for even more selective
pressure and shift toward a Proteobacteria-dominated com-
munity [75]. The positive feedback loop that occurs in
exacerbations is thus similar to the one proposed in Fig. 4,
suggesting that respiratory inflammation, whether acute or
chronic, follows a similar pattern where Proteobacteria
harness the changes in environment due to inflammation to
outcompete other members of the local microbiota.
CONCLUDING REMARKS
For bacterial communities, the environment of the gut and lung,
like cities in a Dickens novel, are distinct but at the same time
quite similar [1, 2, 4–6, 79]. The gut experiences high shear flow
and nutrient availability; the healthy respiratory tract does not.
The gut is nearly uniform in temperature across its length; the
respiratory tract is not. The surface of the gut is lined with mucus;
the distal respiratory tract is not, but is bathed instead in lipid-
rich surfactant. The gut is largely anaerobic; the healthy
respiratory tract is not. However, neither site supports anaerobic
respiration, but this tale changes in the setting of chronic
inflammation, in which the lung is flooded with mucus to create
anaerobic zones and, in both the gut and lungs, dense
concentrations of RNS that selectively favor the growth of
facultative anaerobic Gammaproteobacteria. In short, host
inflammation propels a convergence of the environmental
growth conditions within these 2 organs, and bacterial growth in
the diseased respiratory tract comes to resemble that in diseased
colons. There is far, far more to uncover as it relates to
inflammation and promotion of chronic bacterial growth in this
emerging tale of two sites.
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